3种高血压治疗方案的药物经济学评价  

Pharmacoeconomic Evaluation of Medium and Severe Hyperpietics Treated by Three Pharmacotherapeutic Schemes

作　　者：姚晖[1] 张继平[1] 黄志红[1] 

机构地区：[1]佛山市第二人民医院药剂科,广东佛山528000

出　　处：《国际医药卫生导报》2007年第9期126-129,共4页International Medicine and Health Guidance News

摘　　要：目的对单独使用拜新同、拜新同与科素亚合用或与海捷亚合用治疗中重度原发性高血压的3组方案进行药物经济学评价。方法选择45例中重度原发性高血压患者，随机分成3组，每组各15例。拜新同组：单用拜新同3Omg，qd；拜新同与科素亚合用组：拜新同30mg，qd，加科素亚50mg，qd；拜新同与海捷亚合用组：拜新同30mg，qd，加海捷亚62．5mg，qd；3组疗程均为12周，观察3组治疗疗效。结果3组治疗方案在治疗中、重度高血压上治疗效果有显著差异，成本也有显著差异。结论拜新同联合海捷亚疗效高且更为经济。Objective To evaluate three shemes of medium and severe idiopathic hypertension treatment. Methods Forty five cases with of medium and severe idiopathic hypertension were randomly and averagely assigned to three grounps as follows, Adalat group, Adalat and Cozaar combination group, Adalat and Hyzaar combination group. The first group only used Adalat 30 mg once daily, the second group used Adalat 30 mg and Cozaar 50 mg once daily, and the third group used Adalat 30 mg and Hyzaar 62.5 mg once daily. The course of treatment for all three groups had last out 12 weeks. Results While there was a significant difference in the Adalat group, Adalat and Cozaar combination group, Adalat and Hyzaar combination group when they were used to treat medium and severe idiopathic hypertension, there was a significant difference in the costs involved. Conclusion Adalat and Hyzaar combination group shows higher therapeutic effect and less economic cost.

关 键 词：高血压 药物经济学 成本效果分析法 敏感度分析 

分 类 号：R544[医药卫生—心血管疾病]